Multiple Myeloma

The combination of cevostamab, pomalidomide, and dexamethasone was deemed safe with early efficacy signals in relapsed/refractory multiple myeloma.

Early and promising efficacy was shown with elranatamab added to daratumumab/lenalidomide in transplant-ineligible, newly diagnosed multiple myeloma.

Two denosumab biosimilars received approval from the FDA for the purpose of increasing bone mass in individuals at high risk for fracture.

An HMR risk signature predicted outcomes in multiple myeloma, linked with genomic instability, immune microenvironment, and drug sensitivity.

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Experts preview abstracts being presented at IMS, highlighting the role of MRD, bispecific antibodies, and other strategies to refine myeloma management.

Panelists discuss how trispecific antibodies targeting multiple antigens show promise for preventing antigen escape, while identifying ultrahigh-risk patients, frail patients, optimal treatment duration, and therapy access as key unmet needs.

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Panelists discuss how academic centers can partner with community practices through early engagement, initial step-up dosing support, and education to overcome barriers to bispecific adoption.

Panelists discuss how the RedirecTT-1 combination of talquetamab and teclistamab shows promising efficacy in extramedullary disease (EMD) with a 79% overall response rate, though with increased infectious complications.

Shahzad Raza, MD, highlights the challenges associated with managing relapsed/refractory multiple myeloma with extramedullary disease.

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Panelists discuss how to identify and manage GPRC5D-related toxicities, including skin rash, nail problems, and dysgeusia, emphasizing patient education, nutritional support, and dose modification strategies.

Panelists discuss how they've transitioned to outpatient step-up dosing models with robust supportive care protocols, including pneumocystis jirovecii pneumonia (PJP) prophylaxis, intravenous immunoglobulin (IVIG) therapy, and hospital-at-home support teams.

Meletios A. Dimopoulos, MD, discusses the efficacy of BVd vs DVd in patients with relapsed or refractory multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the feasibility of daratumumab plus KRd as a standard of care for the management of newly diagnosed multiple myeloma.

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

Panelists discuss how real-world bispecific data shows slight efficacy drops compared with clinical trials but still demonstrates effectiveness in patients who wouldn't meet trial criteria, particularly for bridging to chimeric antigen receptor (CAR) T-cell therapy